CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of multiple myeloma (MM), Waldenström macroglobulinemia (WM) and amyloidosis.
  
  OVERVIEW OF ACTIVITY
  Hematologic cancers include the lymphomas, the leukemias, MM and other related disorders stemming from lymphoid and myeloid progenitor cell lines. Taken together, it is estimated that approximately 174,250 new lymphoid, myeloid and leukemic cancer cases will be identified in the United States in the year 2018, and 58,100 individuals will die from these diseases. Importantly, more than 70 drug products are currently labeled for use in the management of hematologic cancers with more than 120 distinct FDA-approved indications. Although this extensive list of available treatment options is reassuring for patients and oncology healthcare professionals, it poses a challenge to the practicing clinician who must maintain up-to-date knowledge of their appropriate application across a vast spectrum of tumor types. This is particularly true within the realm of MM, WM and amyloidosis, where the past several years have yielded a staggering number of important clinical and research advances.
  
  These proceedings from a CME symposium during the ASH Annual Meeting use the perspectives of a group of community oncologists/hematologists gathered during a daylong working group to establish and subsequently address some of the most frequently encountered questions and controversies facing clinicians involved in the management of these diseases. By providing information on the latest research developments and their potential application to routine practice, this activity is designed to assist hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of MM, WM and amyloidosis with the formulation of up-to-date clinical management strategies.
  
  LEARNING OBJECTIVES

  • Customize the use of induction, consolidation and maintenance therapeutic approaches for patients with MM in the post-transplant and nontransplant settings, considering patient- and disease-related factors, including cytogenetic profile.
  • Consider published research data and other clinical factors in the best-practice selection, sequencing or combining of available therapies in the nonresearch care of patients with relapsed/refractory (R/R) MM.
  • Appreciate the mechanisms of action of, supportive research database with and FDA-endorsed indications for monoclonal antibodies directed at CD38 and SLAMF7, and effectively identify where and how these agents should be integrated into the clinical management of newly diagnosed and R/R MM.
  • Design and implement a plan of care for patients with smoldering myeloma, considering the applicability of existing and emerging clinical trial data.
  • Develop an evidence-based algorithm for the use of stem cell transplant, chemotherapy and/or novel targeted agents in the management of primary amyloidosis.
  • Consider clinical and other patient-related factors in the sequence and selection of systemic therapy for patients with WM requiring active treatment.
  • Assess the ongoing clinical trials evaluating novel investigational approaches for MM, WM and amyloidosis, and obtain consent from appropriate patients for study participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:
  
  Rafael Fonseca, MD
  Getz Family Professor of Cancer
  Chair, Department of Internal Medicine
  Mayo Clinic Arizona
  Scottsdale, Arizona
  
  Advisory Committee: AbbVie Inc, Aduro Biotech, Amgen Inc, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Janssen Biotech Inc, Juno Therapeutics, Kite Pharma Inc, Merck, Novartis, Pharmacyclics LLC, an AbbVie Company, Sanofi Genzyme, Takeda Oncology; Scientific Advisory Board: Adaptive Biotechnologies.
  
  Sagar Lonial, MD
  Professor and Executive Vice Chair
  Department of Hematology and Medical Oncology
  Chief Medical Officer
  Winship Cancer Institute
  Emory University
  Atlanta, Georgia
  
  Honoraria: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, GlaxoSmithKline, Janssen Biotech Inc, Merck, Novartis, Onyx Pharmaceuticals, an Amgen subsidiary, Takeda Oncology.
  
  Robert Z Orlowski, MD, PhD
  Florence Maude Thomas Cancer Research Professor
  Chair Ad Interim, Department of Lymphoma and Myeloma
  Professor, Department of Experimental Therapeutics
  Division of Cancer Medicine
  The University of Texas MD Anderson Cancer Center
  Houston, Texas
  
  Advisory Committee: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, Janssen Biotech Inc, Kite Pharma Inc, Sanofi Genzyme; Contracted Research: Amgen Inc, BioTheryX Inc, Spectrum Pharmaceuticals Inc.
  
  Noopur Raje, MD
  Director, Center for Multiple Myeloma
  Massachusetts General Hospital Cancer Center
  Professor of Medicine
  Harvard Medical School
  Boston, Massachusetts
  
  Consulting Agreements: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, Janssen Biotech Inc, Merck, Takeda Oncology.
  
  Professor Katja Weisel, MD
  Professor of Medicine
  Head of the Myeloma Center Tübingen
  Head of Oncological Outpatient Clinic
  Deputy Head of Clinical Trials
  University of Tübingen
  Tübingen, Germany
  
  Advisory Committee and Consulting Agreements: Adaptive Biotechnologies, Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, Janssen Biotech Inc, Takeda Oncology; Contracted Research: Amgen Inc, Celgene Corporation, Janssen Biotech Inc, Sanofi Genzyme; Data and Safety Monitoring Board: Amgen Inc, Celgene Corporation, Karyopharm Therapeutics, Oncopeptides.
  
  CONSULTING ONCOLOGISTS/HEMATOLOGISTS — The following consulting oncologists/hematologists (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:
  
  Amy Bessnow, MD, MPH
  Seacoast Cancer Center
  Wentworth-Douglass Hospital
  Dover, New Hampshire
  
  No relevant conflicts of interest to disclose.
  
  Suzanne Cole, MD
  Medical Director
  University Hospital Simmons Cancer Clinic, Richardson-Plano
  Assistant Professor, Division of Hematology and Oncology
  UT Southwestern Medical Center
  Dallas, Texas
  
  No relevant conflicts of interest to disclose.
  
  Jewel Johl, MD
  Diablo Valley Oncology and Hematology Medical Group
  Pleasant Hill, California
  
  No relevant conflicts of interest to disclose.
  
  Kapisthalam S Kumar, MD
  Florida Cancer Specialists
  New Port Richey, Florida
  
  No relevant conflicts of interest to disclose.
  
  Erik Rupard, MD
  Chief, Hematology-Oncology
  McGlinn Cancer Institute
  The Reading Hospital
  West Reading, Pennsylvania
  
  No relevant conflicts of interest to disclose.
  
  Rajni Sinha, MD
  Piedmont Cancer Institute
  Atlanta, Georgia
  
  No relevant conflicts of interest to disclose.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech, Genomic Health Inc, Gilead Sciences Inc, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Genentech, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Pharmacyclics LLC, an AbbVie Company, Seattle Genetics and Takeda Oncology.
  
  Hardware/Software Requirements:
  A high-speed Internet connection
  A monitor set to 1280 x 1024 pixels or more
  Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
  Adobe Flash Player 27 plug-in or later
  Adobe Acrobat Reader
  (Optional) Sound card and speakers for audio
  
  Release date: January 2019
  Expiration date: January 2020